Scholars have recently delved into the pathogenesis and therapeutic opportunities of Treg in BC, with key areas of interest including PD-L1, inflammation, cancer stem cells, prognosis, immunogenic cell death, and other related factors since 2016. This evidence concerns the gene CD274 and breast cancer.